Literature DB >> 18442196

Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis.

Holger G Hass1, Oliver Nehls, Juergen Jobst, Andrea Frilling, Ulrich Vogel, Stephan Kaiser.   

Abstract

AIM: To investigate the molecular pathways involved in human cholangiocarcinogenesis by gene expression profiling.
METHODS: Oligonucleotide arrays (Affymetrix U133A) were used to establish a specific gene expression profile of intrahepatic CCC in comparison to corresponding non-malignant liver tissue. To validate the expression values of the most overexpressed genes, RT-PCR experiments were performed.
RESULTS: Five hundred and fifty-two statistically differentially expressed genes/ESTs (221 probes significantly up-regulated, 331 probes down-regulated; P < 0.05; fold change > 2; > or = 70%) were identified. Using these data and two-dimensional cluster analysis, a specific gene expression profile was obtained allowing fast and reproducible differentiation of CCC, which was confirmed by supervised neuronal network modelling. The most consistently overexpressed gene (median fold change 33.5, significantly overexpressed in 100%) encoded osteopontin. Furthermore, an association of various genes with the histopathological grading could be demonstrated.
CONCLUSION: A highly specific gene expression profile for intrahepatic CCC was identified, allowing for its fast and reproducible discrimination against non-malignant liver tissue and other liver masses. The most overexpressed gene in intrahepatic CCC was the gene encoding osteopontin. These data may lead to a better understanding of human cholangiocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18442196      PMCID: PMC2708360          DOI: 10.3748/wjg.14.2501

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  46 in total

1.  Validation of array-based gene expression profiles by real-time (kinetic) RT-PCR.

Authors:  M S Rajeevan; S D Vernon; N Taysavang; E R Unger
Journal:  J Mol Diagn       Date:  2001-02       Impact factor: 5.568

Review 2.  The regulation and role of osteopontin in malignant transformation and cancer.

Authors:  Mohamed K El-Tanani; Frederick Charles Campbell; Vittal Kurisetty; Dachuan Jin; Mella McCann; Philip S Rudland
Journal:  Cytokine Growth Factor Rev       Date:  2006-11-17       Impact factor: 7.638

3.  Differential expression of osteonectin/SPARC during human prostate cancer progression.

Authors:  R Thomas; L D True; J A Bassuk; P H Lange; R L Vessella
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

4.  Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma.

Authors:  K S Suh; H R Roh; Y T Koh; K U Lee; Y H Park; S W Kim
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

5.  Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer.

Authors:  Zhi Hu; Dongmei Lin; Jingsong Yuan; Ting Xiao; Husheng Zhang; Wenyue Sun; Naijun Han; Ying Ma; Xuebing Di; Meixia Gao; Jinfang Ma; Junhang Zhang; Shujun Cheng; Yanning Gao
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

6.  The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma.

Authors:  Hui Zhang; Qing-Hai Ye; Ning Ren; Lei Zhao; Yan-Fang Wang; Xin Wu; Hui-Chuan Sun; Lu Wang; Bo-Heng Zhang; Yin-Kun Liu; Zhao-You Tang; Lun-Xiu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-20       Impact factor: 4.553

7.  Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver.

Authors:  A Tannapfel; L Weinans; F Geissler; A Schütz; A Katalinic; F Köckerling; J Hauss; C Wittekind
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

8.  Bcl-2 expression in cholangiocellular carcinoma is inversely correlated with biologically aggressive phenotypes.

Authors:  Y Ito; T Takeda; Y Sasaki; M Sakon; M Monden; T Yamada; S Ishiguro; S Imaoka; M Tsujimoto; N Matsuura
Journal:  Oncology       Date:  2000-06       Impact factor: 2.935

9.  Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3.

Authors:  M Graessmann; B Berg; B Fuchs; A Klein; A Graessmann
Journal:  Oncogene       Date:  2006-12-11       Impact factor: 9.867

Review 10.  The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis.

Authors:  Goutam Chakraborty; Shalini Jain; Reeti Behera; Mansoor Ahmed; Priyanka Sharma; Vinit Kumar; Gopal C Kundu
Journal:  Curr Mol Med       Date:  2006-12       Impact factor: 2.222

View more
  14 in total

1.  Osteopontin promoter polymorphisms at locus -443 are associated with metastasis and poor prognosis of human intrahepatic cholangiocarcinoma in Chinese population.

Authors:  Xiang-Qian Zhao; Huan-Xian Ma; Mao-Sheng Su; Lei He
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells.

Authors:  Xin-Lin Wu; Kai-Jin Lin; Ai-Ping Bai; Wan-Xiang Wang; Xing-Kai Meng; Xiu-Lan Su; Ming-Xing Hou; Pei-De Dong; Jun-Jing Zhang; Zhao-Yang Wang; Lin Shi
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

3.  Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Somsak Likhitrattanapisal; Jaitip Tipanee; Tavan Janvilisri
Journal:  Tumour Biol       Date:  2016-07-22

4.  Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer.

Authors:  Dipok Kumar Dhar; Steven W M Olde Damink; James Hal Brindley; Andrew Godfrey; Michael H Chapman; Neomal S Sandanayake; Fausto Andreola; Sybille Mazurek; Tayyaba Hasan; Massimo Malago; Stephen P Pereira
Journal:  Cancer       Date:  2012-08-01       Impact factor: 6.860

5.  Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets.

Authors:  Q-X Huang; J-Y Cui; H Ma; X-M Jia; F-L Huang; L-X Jiang
Journal:  Cancer Gene Ther       Date:  2015-12-18       Impact factor: 5.987

6.  Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases.

Authors:  Marut Laohaviroj; Yaovalux Chamgramol; Chawalit Pairojkul; Jason Mulvenna; Banchob Sripa
Journal:  Asian Pac J Cancer Prev       Date:  2016

7.  Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma.

Authors:  Min-A Seol; In-Sun Chu; Mi-Jin Lee; Goung-Ran Yu; Xiang-Dan Cui; Baik-Hwan Cho; Eun-Kyung Ahn; Sun-Hee Leem; In-Hee Kim; Dae-Ghon Kim
Journal:  BMC Cancer       Date:  2011-02-19       Impact factor: 4.430

Review 8.  An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.

Authors:  Pattaya Seeree; Phorutai Pearngam; Supeecha Kumkate; Tavan Janvilisri
Journal:  Int J Genomics       Date:  2015-09-02       Impact factor: 2.326

9.  Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma.

Authors:  Ming-Huang Chen; Chueh-Chuan Yen; Chi-Tung Cheng; Ren-Chin Wu; Shih-Chiang Huang; Chung-Shan Yu; Yi-Hsiu Chung; Chun-Yu Liu; Peter Mu-Hsin Chang; Yee Chao; Ming-Han Chen; Yu-Fen Chen; Kun-Chun Chiang; Ta-Sen Yeh; Tzu Chi Chen; Chi-Ying F Huang; Chun-Nan Yeh
Journal:  Oncotarget       Date:  2015-09-15

10.  A novel predictive equation for potential diagnosis of cholangiocarcinoma.

Authors:  Ratthaphol Kraiklang; Chawalit Pairojkul; Narong Khuntikeo; Kanokwan Imtawil; Sopit Wongkham; Chaisiri Wongkham
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.